BNET Industries
Market Cap:$36.1M
Last Fiscal Year Sales:$29.5M
- Public
- US
Dow Jones Description
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company committed to improving people's health and confidence through its quality dermatological treatments. DUSA markets and continues to develop its Levulan Photodynamic Therapy (PDT) technology platform, which is a treatment for the pre-cancerous skin lesions known as Actinic Keratoses (AK). DUSA is also developing certain internal indications of Levulan PDT. DUSA's portfolio of complementary dermatology products includes ClindaReach , which was acquired from Sirius Laboratories, Inc. ClindaReach is a topical acne treatment which includes a novel applicator for those hard-to-reach areas.
CFO & Vice President, Finance
Richard C. ChristopherNumber of Employees 84
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
DUSA Pharma DUSA Posts Q3 Loss of 2c, Beats by 2c
News & Analysis
Filter by
dusa pharmaceuticals inc. and financial - All News and Analysis
Speak with other shareholders about: (OTCBB: QMCI), (OTCBB: MBKR), (NASD: DUSA), (OTCBB: OPBL), and (OTC: PAPT) .
M2 PRESSWIRE-18 May 2007-Stockwire.com: Speak with other shareholders about: (OTCBB: QMCI), (OTCBB: MBKR), (NASD: DUSA), (OTCBB: OPBL), and (OTC: PAPT) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:18052007 AUSTIN, TX: Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked...
Alerts: Turning Pennies into dollars: (OTCBB: QMCI), (OTCBB: MBKR), (NASD: DUSA), (OTCBB: OPBL), (OTC: PAPT).
M2 PRESSWIRE-18 May 2007-RealPennies.com: Alerts: Turning Pennies into dollars: (OTCBB: QMCI), (OTCBB: MBKR), (NASD: DUSA), (OTCBB: OPBL), (OTC: PAPT)C1994-2007 M2 COMMUNICATIONS LTD RDATE:18052007 RealPennies.com ALERTS: reporting on dollar volume movers. -- Brought to you by the HagensMedia.com Finance Network...
DUSA Pharmaceuticals adds Jay Haft as new director; reports third quarter financial results
MISSISSAUGA, Ontario--BUSINESS WIRE--Nov. 5, 1996--DUSA Pharmaceuticals, Inc. (NASDAQ, NMS: DUSA) reported today the addition of Jay M. Haft to the DUSA board, and its third quarter financial results. Mr. Haft, an experienced strategic and financial consultant for growth stage companies, is Chairman and/or Director of numerous public...
DUSA Pharmaceuticals reports 1994 financial results and clinical trial progress
MISSISSAUGA, Ontario--BUSINESS WIRE--Feb. 27, 1995--DUSA Pharmaceuticals Inc. (NASDAQ NMS: DUSA, TSE:DSP) released today its audited financial results for the year ended Dec. 31, 1994.The net loss for the year was $3,539,892, or 66 cents per share, compared to $2,248,461, or 44 cents per share, a year earlier.Research and development costs...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Richard C. Christopher | CFO & Vice President, Finance |
| Stuart Marcus | Vice President, Scientific Affairs and Chief Medical Officer |
| William O'Dell | Executive Vice President, Sales & Marketing |
| David Page | Associate Vice President, Sales |
| Mark Carota | Vice President, Operations |
| Michael J. Todisco | Vice President, Controller |
| Paul A. Sowydra | Vice President, Marketing |
| Paul Sowyrda | Vice President, Prod Marketing, Sales |
| Scott Lundahl | Vice President, Regulatory Affairs & Intellectual Property |
| Shari Lovell | Director, Shareholder Services |
| Ed Sinamark | Manager, IT |
| Magnus Moliteus | Consultant |
| Nanette W. Mantell | Secretary |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Jay Haft | ViceChairman |
| D. Geoffrey Shulman | Board of Directors |
| David M. Bartash | Board of Directors |
| John H. Abeles | Board of Directors |
| Richard C. Lufkin | Board of Directors |
| Robert F Doman | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | CFO & Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Vice President, Scientific Affairs and Chief Medical Officer | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Executive Vice President, Sales & Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Associate Vice President, Sales | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Vice President, Operations | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Vice President, Controller | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Vice President, Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Vice President, Prod Marketing, Sales | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Vice President, Regulatory Affairs & Intellectual Property | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Director, Shareholder Services | Current |
| DUSA Pharmaceuticals, Inc. | Director, Shareholder Services | Former |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Manager, IT | Current |
| Organization | Position | Status |
|---|---|---|
| Columbus Nova | Partner | Current |
| DUSA Pharmaceuticals, Inc. | ViceChairman | Current |
| Reable Therapeutics, Inc. | Chairman | Current |
| CompuCom | Chairman | Current |
| Dcap Group, Inc. | Director | Current |
| Concert Association of Florida, Inc | Board Member | Current |
| Dusa | Board of Directors | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| Miami City Ballet Inc. | Treasurer | Current |
| The Haft, Incorporated | Senior Corporate Partner | Former |
| Rosoff | Senior Corporate Partner | Former |
| Oryx Technology Corp | Former | |
| Yale University | B.A. | Former |
| Yale College | B.S. | Former |
| Yale University | Degree | Former |
| Columbus Nova | Member | Former |
Magnus Moliteus is a consultant to the healthcare industry and Chairman of COM Consulting Inc., a privately held firm, which enhances Swedish-American relations particularly between health care companies. From 1995 to 2001, when he became a full-time consultant, Mr. Moliteus served as Executive Director of Invest in Sweden Agency, U.S., a Swedish government agency. From 1977 to 1990, he was Chief Executive Officer of Pharmacia, Inc. (now owned by Pfizer, Inc.)
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Consultant | Current |
| Dusa | Consultant | Current |
| Dusa | Board of Directors | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| Pharmacia Corporation | Chief Executive Officer | Former |
| Invest.Com | Executive Director | Former |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Secretary | Current |
| DUSA Pharmaceuticals, Inc. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| DUSA Pharmaceuticals, Inc. | Chairman & CEO | Former |
| Draxis Health, Inc. | President | Former |
| Draxis Health, Inc. | Director | Former |
David M. Bartash, is the President and founder of Bartash and Company, a consulting company which, since 1990, has been providing consulting services for the healthcare industry, including research for the healthcare investment community and support services for venture start-ups.
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
Array
| Organization | Position | Status |
|---|---|---|
| MedVest, Inc. | President | Current |
| Dusa | Board of Directors | Current |
| New York Academy of Sciences | Board of Directors | Current |
| Etubics Corporation | Board of Directors | Current |
| I-Flow Corporation | Board of Directors | Current |
| Cytocore, Inc. | Board of Directors | Current |
| Prescient Medical, Inc | Board of Directors | Current |
| Combimatrix Corporation | Director | Current |
| Cytocore Inc | Board of Directors | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| New York Academy of Sciences | Member | Current |
| Kidder, Peabody & Co. | Healthcare Analyst | Former |
| Pfizer Inc. | Clinical Research Medical Executive | Former |
| Sterling Drug | Clinical Research Medical Executive | Former |
| University of Birmingham | Degree In Pharmacology | Former |
| Oryx Technology Corp | member | Former |
Richard C. Lufkin is the principal of Enterprise Development Associates, through which he provides consulting and venture support services to early stage technology-based companies. He is a founder of several firms, principally in the pharmaceutical, biotechnology, and medical device fields.
| Organization | Position | Status |
|---|---|---|
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| Linguagen Corp | Chief Financial Officer | Former |
Robert F. Doman, has been employed by the Company as President and Chief Operating Officer since January 2005. From 2000 until 2004, Mr. Doman served as President of Leach Technology Group, the medical device division of Leach Holding Corporation. From 1999 to 2000, he was President, Device Products Development, of West Pharmaceutical Services, a manufacturer of systems and device components for parentally administered medicines and drugs. Prior to joining West Pharmaceutical Services, he worked for the Convatec division of Bristol-Myers Squibb from 1991 to 1999 in positions that included: Vice President, Worldwide Marketing and Business Development; Vice President and General Manager, U.S. Wound and Skin Care; and Vice President, U.S. Operations.
| Organization | Position | Status |
|---|---|---|
| Dusa | President and Chief Executive Officer | Current |
| Dusa | Board of Directors | Current |
| DUSA Pharmaceuticals, Inc. | Board of Directors | Current |
| West Pharmaceutical Services, Inc. | President | Former |
Executive News
-
DUSA Pharmaceuticals (DUSA) Reports Second Quarter 2009 Corporate Highlights and Financial Results Q2
-
DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes



